Taken together, these data show that computationally predicted RCAN1-422-32-reactive TCR-T cells from similar TCR groups can generate RCAN1-422-32-MHC-dependent cytotoxicity in vitro and in vivo and reveal RCAN1-4 SJe4/e5 as a novel immunogenic target for immunotherapy in GBM. This evidence concerns the gene HLA-C and glioblastoma.